A few days ago I asked you to write an essay of no more than 150 words to answer a question from the Bath Spa University Banking & Finance course. A few of you tried as you can see here but I have good news and bad.
This should be easy, I invite you to answer the following question in fewer than 150 words. Bath Spa students need to find a safe space room if their human rights are breached by being asked to pen more than 150 words a term. The deadline for entries is Sunday at midnight and the best entry wins a bottle of Greek Hovel 2019 olive Oil. This question is sponsored by Ms Alison Rose of RBS.
Chris Bailey's article Has Fevertree (FEVR) completely lost its fizz? by Chris Bailey (spoiler alert: it's the top non-Tom story) made me think about the wider drinks industry.
I clarify my share purchase ion Otibiotix (OPT). I discuss the revelations yesterday about the breakdown of historic income at Versarien (VRS) explaining, to BBMs who claim it does not, exactly why it does matter! Then I discuss whether Terry Smith's golden run is about to break badly for him. Do not get me wrong, I think Smith is an absolute top banana but I have a doubt or two.
Terry Smith's funds were not recommended to its clients by Hargreaves Lansdown (HL). Those of Neil Woodford were. Of course, that was noting to do with the fees Hargreaves received from the two forms. No, not at all. In his annual newsletter the great Smith has slated Woodford. There is nothing that should surprise ShareProphets readers but it is all good stuff. Smith opines:
To emphasise the point about the contrasting investment strategies of Neil Woodford and Terry Smith that I covered earlier today, I thought it appropriate to cover the health-tech AI spoof, BenevolentAI, that has just filed its results for the year to 31 December 2017 at Companies House (HERE). I am still struggling to find any evidence of anything other than a reasonably good concept here.....and it’s meant to be worth $2 billion!
It is hard not to compare these two behemoths of the UK fund management industry. Neil Woodford has (still) a great long-term track record but the recent respective performances of their flagship funds are chalk and cheese and now Terry Smith is looking to encroach on Woodford’s territory further with a small company investment trust too.
Base rates are going to stay low forever so current (inflated) equity market valuations are justifiable. In other words "it will be different this time". I don't believe that and neither does Andrew Monk of VSA. But the great Terry Smith argues it might be...who are we to argue with Terry?
The most excellent BestInvest has today published its annual "Spot the Dog" Review of British based fund managers and - by value - around half of the cash invested in funds it terms dogs sits at M&G. And the worst fund manager among those managing UK equities only is Tom Dobell at M&G, the man who likes chucking other people's money at fraudster Rob Terry of Quindell over and over again. Among the heroes is, naturally Terry Smith of Fundsmith, the best performer in the "global" category. The full listings of dogs in each sector is fascinating. Well done Dobell, you are, if nothing else, consistent. That is to say consistently useless.
Following the mammoth success of UK Investor Show 2014 we are moving into overdrive for the 2015 show on April 18 and one new feature will be a series of 14 one hour masterclasses with an audience limited to 80 – we are taking on an additional floor in Westminster.